GLP-1 medications: a patient's guide to Ozempic, Mounjaro, Wegovy, and Zepbound

GLP-1 receptor agonists have changed how we treat Type 2 diabetes and obesity. Here is what they are, how they work, what to expect, and the honest tradeoffs no one tells you about.

By Rakesh Patel, DO Β· Last reviewed 2026-05-25

GLP-1 medications have gotten a lot of attention over the last few years β€” and for good reason. They are genuinely effective for Type 2 diabetes and weight management in ways we have not seen from medications before. But the internet is full of hype, horror stories, and half-truths. This guide is our attempt to give you a clear, honest picture of what these medications are, how they work, and what to realistically expect.

What is a GLP-1 medication, in plain English?

Your gut naturally makes a hormone called GLP-1 (glucagon-like peptide-1) when you eat. It signals your pancreas to release insulin, tells your brain you are satisfied, and slows down how fast your stomach empties. GLP-1 medications are engineered to mimic β€” and significantly amplify β€” this natural signal. They are sometimes called incretin mimetics, but all that means is: they copy a hormone your body already makes, just at higher levels and for longer than your natural version would last.

The newer dual-agonist medications like Mounjaro and Zepbound go one step further. They activate both GLP-1 and a second gut hormone called GIP. That combination appears to be even more effective β€” particularly for weight loss β€” than GLP-1 alone.

The brand-name landscape

There are more options than most patients realize, and the name on the box matters because different formulations are approved for different purposes:

  • Ozempic (semaglutide, weekly injection) β€” FDA-approved for Type 2 diabetes. Also has strong cardiovascular outcome data.
  • Trulicity (dulaglutide, weekly injection) β€” FDA-approved for Type 2 diabetes. An older weekly alternative with a good safety record.
  • Mounjaro (tirzepatide, weekly injection) β€” FDA-approved for Type 2 diabetes. Dual GLP-1 + GIP agonist; the most effective for A1C reduction currently available.
  • Rybelsus (oral semaglutide, daily tablet) β€” FDA-approved for Type 2 diabetes. The only oral GLP-1 option; requires taking it on an empty stomach with a small amount of water 30 minutes before eating.
  • Wegovy (semaglutide, weekly injection) β€” FDA-approved specifically for chronic weight management (obesity or overweight with a weight-related condition).
  • Zepbound (tirzepatide, weekly injection) β€” FDA-approved for chronic weight management. The same molecule as Mounjaro, different approval and often different insurance coverage.
  • Saxenda (liraglutide, daily injection) β€” An older daily GLP-1 approved for weight loss. Largely being replaced by weekly options in new patients, but still appropriate in some situations.

The distinction between "diabetes" and "weight loss" approvals matters more for insurance coverage than for biology β€” the medications work through the same mechanisms regardless of label. We will help you navigate which approval pathway makes sense for your situation.

How they actually work

GLP-1 medications work through several mechanisms at once, which is part of why they are so effective:

  • They stimulate insulin release from the pancreas β€” but only when blood sugar is elevated, which is why hypoglycemia (low blood sugar) is rare with GLP-1s alone
  • They suppress glucagon, a hormone that raises blood sugar between meals
  • They slow gastric emptying β€” food moves more slowly from your stomach into your intestine, which blunts blood sugar spikes after meals and makes you feel full sooner
  • They act on appetite centers in the brain, reducing what patients describe as "food noise" β€” the background mental chatter about eating that many people with obesity experience constantly
  • At higher doses, they appear to reduce the rewarding quality of food, which is why some patients notice they simply care less about eating than they used to

What to realistically expect

For Type 2 diabetes: most patients see A1C reductions of 1 to 2 percentage points. Patients on tirzepatide (Mounjaro) in clinical trials saw reductions closer to 2 to 2.5 points. That is meaningful β€” enough to move many patients from poorly controlled to well controlled, or to reduce or eliminate other diabetes medications.

For weight loss: the numbers are genuinely impressive compared to anything we had before. In the SURMOUNT trials, patients on the highest dose of tirzepatide lost an average of 20-22% of their starting body weight over about 16 months. Semaglutide (Wegovy) averages around 15% in trials. Real-world results vary, but 12-20% of starting weight over a year is reasonable to expect at therapeutic doses.

A few things to set expectations honestly:

  • Most of the weight loss happens in the first 6-12 months. Plateaus are normal and expected β€” they are not a sign the medication stopped working.
  • The dose escalation phase (the first 2-5 months) is when side effects are most noticeable. Most people tolerate the medication better once they reach a stable dose.
  • Individual response varies. Some patients lose much more than average; some lose less. Genetics, baseline metabolic rate, and lifestyle factors all play a role.

Common side effects β€” and how we manage them

The most common side effects are gastrointestinal, and they are usually worst during dose escalation:

  • Nausea is the most frequent complaint, affecting roughly 30-40% of patients. It tends to peak in the first few weeks after a dose increase and then fade. Eating smaller, lower-fat meals and not eating right before bed helps significantly.
  • Constipation is underreported and affects many patients. Staying well hydrated, eating adequate fiber, and sometimes adding a gentle stool softener makes a real difference.
  • Vomiting is less common but can occur, especially if you eat a large meal. If vomiting is persistent, we adjust the dose escalation schedule β€” there is no reason to white-knuckle through significant GI side effects.
  • Gallbladder concerns: rapid weight loss of any cause increases gallstone risk. We discuss this with patients who have gallbladder history or who are losing weight quickly.
  • Pancreatitis is rare but worth knowing about. If you develop severe abdominal pain that radiates to your back, stop the medication and seek care immediately.

Side effects people do not talk about enough

A few effects deserve more honest conversation than they usually get:

  • Muscle loss: GLP-1 medications cause fat loss, but without deliberate effort, some of that weight loss comes from muscle. Adequate protein intake (most adults need 1.2-1.6 grams per kilogram of body weight per day) and resistance exercise are not optional extras β€” they are essential to preserving muscle during treatment. We factor this into our recommendations.
  • "Ozempic face": as patients lose significant amounts of weight, facial fat loss can make the face look more gaunt or aged. This is a body fat redistribution effect of weight loss generally, not something unique to semaglutide, but it is worth knowing about before you start.
  • Reduced food enjoyment: many patients experience a significant drop in food noise and appetite. Most find this a relief. A subset, particularly those with a complicated history around eating, find it disorienting or even distressing. We want to hear about this β€” it is a real experience, not a complaint.

A note on compounded GLP-1 medications

During medication shortages, compounding pharmacies began producing compounded semaglutide and tirzepatide. We understand the appeal β€” the cost difference can be enormous. But we have to be direct with you: the FDA has issued warnings about compounded GLP-1 products, including reports of dosing errors, contamination, and products that do not contain what they claim. The shortage designations that permitted compounding have been lifted for semaglutide and are being resolved for tirzepatide, which means these products are moving into a legal gray area. We are not comfortable prescribing compounded versions and we will always explain our reasoning to any patient who asks.

Insurance, prior authorization, and cost

GLP-1 medications are expensive β€” list prices run $900-$1,300 per month before insurance. Coverage varies dramatically by plan, and the difference between a "diabetes" and "weight loss" approval can mean the difference between a $30 copay and $1,200 out of pocket. Manufacturer savings programs (Novo Nordisk and Eli Lilly both have them) can bring costs down significantly for commercially insured patients. We have a separate article that covers this in detail β€” see "The honest cost of GLP-1 medications" in our library for a deeper breakdown. Our team helps with prior authorization letters, and we are direct with patients about what is and is not realistic for their plan.

What happens if you stop

This is the part that gets glossed over in a lot of media coverage: for most patients, stopping a GLP-1 medication leads to gradual weight regain. Studies show that within one to two years of stopping, most patients return to close to their baseline weight. The medication is managing a chronic condition β€” metabolic dysfunction and appetite dysregulation β€” not curing it.

This does not mean you are on it forever at the same dose. Many patients stabilize at a lower maintenance dose once they reach their goal weight. But framing GLP-1 treatment as a "short course" to reset your metabolism and then stop is not well supported by the evidence. We will have this conversation with you before you start, and we revisit it as your treatment evolves.

Who should not take a GLP-1 medication

These medications are not right for everyone:

  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) β€” this is a contraindication
  • Current or recent pancreatitis
  • Pregnancy or planning to become pregnant (a washout period before conception is recommended)
  • Severe gastroparesis β€” slowing gastric emptying further can worsen this condition significantly
  • Some eating disorder histories warrant careful discussion before starting

We review your full history before prescribing and explain any specific concerns for your situation.

How we manage GLP-1 patients at EPC

Endocrinology specialist care makes a meaningful difference with these medications. We are not prescribing from a checklist β€” we are integrating the GLP-1 into a broader metabolic picture that includes your thyroid, your adrenal function, your diabetes trajectory, and your cardiovascular risk profile.

In practice, that means:

  • Lab monitoring every 3-6 months (A1C, kidney function, liver enzymes, and others depending on your baseline)
  • Deliberate dose optimization β€” we do not rush to the maximum dose, and we do not keep patients at a dose that is causing significant side effects
  • Adjusting or deprescribing other medications as your diabetes improves β€” many of our patients are able to reduce or discontinue other agents
  • Coordination with your primary care doctor and, where relevant, your cardiologist
  • Virtual follow-up visits at both our Houston and Katy locations for patients who are stable β€” so you are not driving in for every check-in

If you are already on a GLP-1 started elsewhere and want specialist oversight, we see those patients too. Transitions of care are a normal part of what we do.

Ready to talk?

GLP-1 medications are not magic, but they are the most effective tools we have had for Type 2 diabetes management and medically supervised weight loss in a generation. If you want to explore whether one is right for you β€” or if you are already on one and want to make sure your care is optimized β€” we are glad to see you at either our Houston or Katy location, or virtually for established patients. Request an appointment and we will start with a full picture of where you are now.

Want to talk to one of our clinicians?

New and existing patients welcome. Most major commercial plans and Medicare accepted. Two Houston-area locations and virtual visits available.

Privia Medical Group
PROUD TO BE PART OF PRIVIA MEDICAL GROUP

Endocrine and Psychiatry Center is a proud member of Privia Medical Group. The best doctors in our community have joined together to form Privia Medical Group (PMG), a multi-specialty, high-performance medical group that puts patients first. Our physicians are united by the mission of providing better, more coordinated care for their patients. To learn more about Privia Medical Group and find other Privia doctors, please visit our website.